NTNicholas Teodoro

Nicholas Teodoro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicholas Teodoro has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Lisa Rahangdale

    University of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, School of Medicine, Chapel Hill, North Carolina, United States of America

    5 shared publications
  • Carla J. Chibwesha

    University of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, School of Medicine, Chapel Hill, North Carolina, United States of America

    4 shared publications
  • Jessica R. Keys

    University of North Carolina at Chapel Hill, Center for AIDS Research (CFAR), School of Medicine, Chapel Hill, North Carolina, United States of America

    4 shared publications
  • Katie R. Mollan

    University of North Carolina at Chapel Hill, Center for AIDS Research (CFAR), School of Medicine, Chapel Hill, North Carolina, United States of America

    4 shared publications
  • Masangu Mulongo

    University of the Witwatersrand, Clinical HIV Research Unit (CHRU), Department of Internal Medicine, Faculty of Health Sciences, Johannesburg, South Africa

    4 shared publications
  • Sibusisiwe Gumede

    University of the Witwatersrand, Clinical HIV Research Unit (CHRU), Department of Internal Medicine, Faculty of Health Sciences, Johannesburg, South Africa

    4 shared publications

Latest Publications

  • Open Access

    Efficacy of Combination Treatment for Cervical Precancer Among Women Living with HIV in South Africa: Secondary Outcomes from the ACT 2 Randomized Controlled Trial

    by Carla J. Chibwesha, Nicholas S. Teodoro, Katie R. Mollan, Jessica R. Keys, Chuning Liu, Masangu Mulongo, Sibusisiwe Gumede, Tafadzwa Pasipamire, Mark Faesen, Lisa Rahangdale

    Objective: We report secondary histologic and high-risk HPV (hrHPV) outcomes from the Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living with HIV (ACT 2) Trial. Methods: We conducted a double-blind Phase 2b feasibility trial of loop electrosurgical excision procedure (LEEP) combined with adjuvant intravaginal 5-fluorouracil (5FU) cream. Women living with HIV (WLWH) and cervical intraepithelial neoplasia (CIN) 2/3 underwent LEEP and were randomly assigned (1:1) to receive 8 doses of 5FU or placebo cream. Our secondary outcomes were (a) regression of cervical disease and (b) clearance of hrHPV. Results: From March 2023 to January 2025, 180 participants underwent LEEP and were randomized to 5FU or placebo cream. Median age was 41 years (IǪR: 35-45), 29% had HPV16, 18% had HPV18/45; 99% of women were virologically suppressed (<200 copies/mL) and median CD4 count was 636 cells/uL (IǪR: 376-873). 172 participants (95.6%) completed follow-up. At week 24, 96.3% (78/81) in the 5FU group and 82.0% (73/89) in the placebo group regressed to CIN1 or normal histology (PD 14.3%, CI 5.3%, 23.3%). Among participants with positive LEEP margins at week 0, 88.0% (22/25) in the 5FU versus 61.3% (19/31) in the placebo group regressed to CIN1 or normal (PD 26.7%, CI 5.4%, 48.1%). Genotype-specific hrHPV clearance was similar in both groups (5FU: 58.0%, 40/69; Placebo: 53.8%, 43/80; PD 4.2%, CI −11.7%, 20.2%). Conclusion: Clinical outcomes from our Phase 2b trial demonstrates that intravaginal 5FU post-LEEP may be a beneficial adjuvant treatment for CIN2/3. Clinical Trial Registration: NCT05413811

  • Open Access

    Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among Women Living with HIV in South Africa: Primary Outcomes from the ACT 2 Randomized Trial

    by Nicholas S. Teodoro, Katie R. Mollan, Jessica R. Keys, Chuning Liu, Masangu Mulongo, Sibusisiwe Gumede, Tafadzwa Pasipamire, Mark Faesen, Melissa A. Mischell, Lisa Rahangdale, et al.

    Objective: Determine acceptability and feasibility of loop electrosurgical excision procedure (LEEP) combined with adjuvant intravaginal 5-fluorouracil (5FU) for treatment of cervical intraepithelial neoplasia grade 2/3 (CIN2/3) in women living with HIV (WLWH). Design: Double-blind, randomized, placebo-controlled Phase 2b feasibility trial. Setting: Public-sector hospital in Johannesburg, South Africa. Population: 180 WLWH aged 18+ years with CIN2/3 confirmed by LEEP and on antiretroviral therapy for ≥60 days. Methods: Participants underwent LEEP and were randomly assigned (1:1) to receive 8 doses of adjuvant 5FU or placebo cream every other week and followed for 24 weeks. Main Outcome Measures: The primary outcomes were acceptability and feasibility (adherence, retention, safety, tolerability). Results: Between March 2023 and January 2025, we randomized 180 WLWH. Median age was 41 years (interquartile range [IQR]: 35–45), median CD4+ count was 636 cells/mm³ (IQR: 376–873), and 98.9% were virologically suppressed. Acceptability (>94%) and adherence (>91%) were high and comparable between arms. Retention exceeded 92% in both arms, although Week 24 attendance was lower in the 5FU arm (92.2% vs. 98.9%, probability difference [PD] -6.7%, 95% confidence interval [CI] -14.4%, -0.5%). Safety events were mild, more common with 5FU, and primarily reported as Grade 1 or 2 cervical inflammation (49.2% vs. 26.7%, risk difference [RD] 22.5%, 95% CI 8.6%, 36.4%). One Grade 3 adverse event (an allergic reaction to 5FU) resulted in treatment discontinuation. Conclusions: LEEP plus adjuvant intravaginal 5FU is acceptable and feasible among WLWH in South Africa, supporting progression to a Phase 3 trial. Clinical Trial Registration: NCT05413811. Funding: United States National Institutes of Health (R01CA250850).


  • Open Access

    Randomized clinical trial protocol: Acceptability and feasibility of combination treatment for cervical precancer among South African women living with HIV (ACT 2)

    by Carla J. Chibwesha, Katie R. Mollan, Nicholas S. Teodoro, Jessica R. Keys, Chuning Liu, Masangu Mulongo, Sibusisiwe Gumede, Tafadzwa Pasipamire, Mark Faesen, Lisa Rahangdale


  • Open Access

    ACT 2 Clinical Trial Design: Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living with HIV

    by Carla J. Chibwesha, Katie R. Mollan, Nicholas S. Teodoro, Jessica R. Keys, Chuning Liu, Masangu Mulongo, Sibusisiwe Gumede, Tafadzwa Pasipamire, Mark Faesen, Lisa Rahangdale

    Background: Global efforts to eliminate cervical cancer currently focus on expanding access to HPV vaccination and cervical screening. However, these efforts lack equal investment in treatment of precancerous cervical intraepithelial neoplasia grade 2/3 (CIN2/3), particularly among women with HIV (WWH). This gap leaves a generation of WWH at high risk of persistent/recurrent CIN2/3 and progression to cervical cancer, as standard surgical treatments alone are far less effective in this population. Methods and Design: After randomization, WWH with CIN2/3 (N=180) are randomly allocated to undergo Loop Electrosurgical Excision Procedure (LEEP) followed by self-administration of 8 doses of intravaginal 5% 5-fluorouracil (5FU) or placebo cream (one dose every other week for 16 weeks). Women will be followed for 24 weeks. The primary outcomes are acceptability and feasibility (safety, tolerability, adherence, retention). Secondary outcomes include (a) regression of cervical disease to CIN1 or normal histology and (b) clearance of the hrHPV genotype(s) identified in baseline cervical ThinPrep samples. Discussion: We hypothesize that topical 5FU, a widely available low-cost generic drug, can be repurposed as an adjuvant treatment for CIN2/3 to be self-administered after surgical excision (or ablation) to reduce the risk of persistent/recurrent CIN2/3 and progression to cervical cancer among WWH. In preparation for a large-scale trial to test the effectiveness of combination treatment for CIN2/3 in WWH, we are conducting a Phase 2b feasibility trial of LEEP combined with intravaginal 5FU. Trial Registration: ClinicalTrials.gov , NCT05413811 .

  • Open Access

    Eliminating cervical cancer as a global public health problem requires equitable action

    by Lisa Rahangdale, Nicholas Teodoro, Lameck Chinula, Noel T Brewer

    We need action to reduce inequities in vaccination, screening, and treatment in order to prevent cervical cancer and make elimination a reality everywhere—not just in high income countries, write Lisa Rahangdale and colleagues


  • Intrauterine Fetal Transfusion

    by Nicholas Teodoro, Leanna Sudhof, Scott A. Shainker

  • Long-acting reversible contraception knowledge, attitudes and use among HIV-infected and -uninfected women and their providers

    by Nicholas Teodoro, Annie Fu, N. Tanya Ohly, Noga Shalev, Dara Matseoane-Peterssen, Carolyn L. Westhoff


  • Missing the Gorilla

    by Nicholas Teodoro

  • Open Access

    Cholera in the time of war: implications of weak surveillance in Syria for the WHO's preparedness—a comparison of two monitoring systems

    by Annie Sparrow, Khaled Almilaji, Bachir Tajaldin, Nicholas Teodoro, Paul Langton

    Background Public health breakdown from the Syrian government's targeting of healthcare systems in politically unsympathetic areas has yielded a resurgence of infectious diseases. Suspected cholera recently reappeared but conflict-related constraints impede laboratory confirmation. Given the government's previous under-reporting of infectious outbreaks and the reliance of the WHO on government reporting, we sought to assess the reliability of current surveillance systems. Methods We compared weekly surveillance reports of waterborne diseases from the Syrian government's (WHO-associated) Early Warning and Response System (EWARS), based in Damascus, and the independent, non-governmental Early Warning and Response Network (EWARN) headquartered in Gaziantep, Turkey. We compared raw case rates by EWARS and EWARN and assessed the quality of reporting against the WHO benchmarks. Results We identified significant under-reporting and delays in the government's surveillance. On average, EWARS reports were published 24 days (range 12–61) after the reference week compared with 11 days (5–21) for EWARN. Average completeness for EWARS was 75% (55–84%), compared with 92% for EWARN (85–99%). Average timeliness for EWARS was 79% (51–100%), compared with 88% for EWARN (70–97%). EWARS made limited use of rapid diagnostic tests, and rates of collection of stool samples for laboratory cholera testing were well below reference levels. Conclusions In the context of the current Syrian war, the government's surveillance is inadequate due to lack of access to non-government held territory, an incentive to under-report the consequence of government attacks on health infrastructure, and an impractical insistence on laboratory confirmation. These findings should guide the WHO reform for surveillance in conflict zones.